Perspectives and limitations of microarray-based gene expression profiling of thyroid tumors

Endocrine Reviews

Volumn 28, Issue 3, 2007, Pages 322-338

  Eszlinger, Markus ^a   Krohn, Knut ^a,b   Kukulska, Aleksandra ^c   Jarza̧b, Barbara ^c   Paschke, Ralf ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PROTEIN PATCHED; PROTEIN RET; RAS PROTEIN;

ANALYTICAL EQUIPMENT; ASPIRATION CYTOLOGY; BIOINFORMATICS; CANCER CYTODIAGNOSIS; CANCER DIAGNOSIS; CARCINOGENESIS; CHROMOSOME ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; GENE EXPRESSION PROFILING; GENE MUTATION; GENE REARRANGEMENT; GENETIC ALGORITHM; HUMAN; MICROARRAY ANALYSIS; NONHUMAN; PATHOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; THYROID ADENOMA; THYROID FOLLICULAR CARCINOMA; THYROID NODULE; THYROID PAPILLARY CARCINOMA; THYROID TUMOR;

GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC SCREENING; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; THYROID NEOPLASMS;

EID: 34250799882     PISSN: 0163769X     EISSN: 0163769X     Source Type: Journal    
DOI: 10.1210/er.2006-0047     Document Type: Review

References (164)

1. Gershon D 2002 Microarray technology: an array of opportunities. Nature 416:885-891
2. Gress TM, Hoheisel JD, Lennon GG, Zehetner G, Lehrach H 1992 Hybridization fingerprinting of high-density cDNA-library arrays with cDNA pools derived from whole tissues. Mamm Genome 3:609-619
3. Schena M, Shalon D, Davis RW, Brown PO 1995 Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270:467-470
4. Fodor SP, Read JL, Pirrung MC, Stryer L, Lu AT, Solas D 1991 Light-directed, spatially addressable parallel chemical synthesis. Science 251:767-773
5. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, Mittmann M, Wang C, Kobayashi M, Horton H, Brown EL 1996 Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 14:1675-1680
6. Chee M, Yang R, Hubbell E, Berno A, Huang XC, Stern D, Winkler J, Lockhart DJ, Morris MS, Fodor SP 1996 Accessing genetic information with high-density DNA arrays. Science 274:610-614
7. Wodicka L, Dong H, Mittmann M, Ho MH, Lockhart DJ 1997 Genome-wide expression monitoring in Saccharomyces cerevisiae. Nat Biotechnol 15:1359-1367
8. Eszlinger M, Krohn K, Paschke R 2001 Complementary DNA expression array analysis suggests a lower expression of signal transduction proteins and receptors in cold and hot thyroid nodules. J Clin Endocrinol Metab 86:4834-4842
9. Cheadle C, Vawter MP, Freed WJ, Becker KG 2003 Analysis of microarray data using Z score transformation. J Mol Diagn 5:73-81
10. Vawter MP, Barrett T, Cheadle C, Sokolov BP, Wood III WH, Donovan DM, Webster M, Freed WJ, Becker KG 2001 Application of cDNA microarrays to examine gene expression differences in schizophrenia. Brain Res Bull 55:641-650
11. van Staveren WC, Solis DW, Delys L, Venet D, Cappello M, Andry G, Dumont JE, Libert F, Detours V, Maenhaut C 2006 From the cover: gene expression in human thyrocytes and autonomous adenomas reveals suppression of negative feedbacks in tumorigenesis. Proc Natl Acad Sci USA 103:413-418
12. Hubbell E, Liu WM, Mei R 2002 Robust estimators for expression analysis. Bioinformatics 18:1585-1592
13. Li C, Wong WH 2001 Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA 98:31-36
14. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP 2003 Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4:249-264
15. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP 2003 Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31:e15
16. Wu Z, Irizarry RA, Gentleman R, Murillo FM, Spencer F 2003 A model-based background adjustment for oligonucleotide expression arrays. Technical report. Baltimore, MD: Johns Hopkins University, Department of Biostatistics Working Papers
17. Shedden K, Chen W, Kuick R, Ghosh D, Macdonald J, Cho KR, Giordano TJ, Gruber SB, Fearon ER, Taylor JM, Hanash S 2005 Comparison of seven methods for producing Affymetrix expression scores based on false discovery rates in disease profiling data. BMC Bioinformatics 6:26
18. Fujarewicz K, Wiench M 2003 Selecting differentially expressed genes for colon tumor classification. Int J Applied Math Comp Science 13:327-335
19. Fujarewicz K, Kimmel M, Rzeszowska-Wolny J, Swierniak A 2003 A note on classification of gene expression data using support vector machines. J Biol Systems 11:43-56
20. Tibshirani R, Hastie T, Narasimhan B, Chu G 2002 Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 99:6567-6572
21. Westfall PH, Young SS 1993 Resampling-based multiple testing: examples and methods for multiple P-value adjustment. New York: John Wiley & Sons
22. Tusher VG, Tibshirani R, Chu G 2001 Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98:5116-5121
23. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES 1999 Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286:531-537
24. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi OP, Wilfond B, Borg A, Trent J 2001 Gene-expression profiles in hereditary breast cancer. N Engl J Med 344:539-548
25. Vapnik V 1995 The nature of statistical learning theory. New York: Springer-Verlag
26. Guyon I, Weston J, Barnhill S, Vapnik V 2002 Gene selection for cancer classification using support vector machines. Machine Learning 64:389-422
27. Aldred MA, Ginn-Pease ME, Morrison CD, Popkie AP, Gimm O, Hoang-Vu C, Krause U, Dralle H, Jhiang SM, Plass C, Eng C 2003 Caveolin-1 and caveolin-2, together with three bone morphogenetic protein-related genes, may encode novel tumor suppressors down-regulated in sporadic follicular thyroid carcinogenesis. Cancer Res 63:2864-2871
28. Giordano TJ, Au AY, Kuick R, Thomas DG, Rhodes DR, Wilhelm Jr KG, Vinco M, Misek DE, Sanders D, Zhu Z, Ciampi R, Hanash S, Chinnaiyan A, Clifton-Bligh RJ, Robinson BG, Nikiforov YE, Koenig RJ 2006 Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation. Clin Cancer Res 12:1983-1993
29. Barden CB, Shister KW, Zhu B, Guiter G, Greenblatt DY, Zeiger MA, Fahey III TJ 2003 Classification of follicular thyroid tumors by molecular signature: results of gene profiling. Clin Cancer Res 9:1792-1800
30. Weber F, Shen L, Aldred MA, Morrison CD, Frilling A, Saji M, Schuppert F, Broelsch CE, Ringel MD, Eng C 2005 Genetic classification of benign and malignant thyroid follicular neoplasia based on a 3-gene combination. J Clin Endocrinol Metab 90.:2512-2521
31. Aldred MA, Huang Y, Liyanarachchi S, Pellegata NS, Gimm O, Jhiang S, Davuluri RV, de la Chapelle A, Eng C 2004 Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol 22:3531-3539
32. Chevillard S, Ugolin N, Vielh P, Ory K, Levalois C, Elliott D, Clayman GL, El Naggar AK 2004 Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications. Clin Cancer Res 10:6586-6597
33. Finley DJ, Zhu B, Barden CB, Fahey III TJ 2004 Discrimination of benign and malignant thyroid nodules by molecular profiling. Ann Surg 240:425-436
34. Lacroix L, Lazar V, Michiels S, Ripoche H, Dessen P, Talbot M, Caillou B, Levillain JP, Schlumberger M, Bidart JM 2005 Follicular thyroid tumors with the PAX8-PPARγ1 rearrangement display characteristic genetic alterations. Am J Pathol 167:223-231
35. Lubitz CC, Gallagher LA, Finley DJ, Zhu B, Fahey III TJ 2005 Molecular analysis of minimally invasive follicular carcinomas by gene profiling. Surgery 138:1042-1049
36. Lui WO, Foukakis T, Liden J, Thoppe SR, Dwight T, Hoog A, Zedenius J, Wallin G, Reimers M, Larsson C 2005 Expression profiling reveals a distinct transcription signature in follicular thyroid carcinomas with a PAX8-PPAR(γ) fusion oncogene. Oncogene 24:1467-1476
37. Puskas LG, Juhasz F, Zarva A, Hackler Jr L, Farid NR 2005 Gene profiling identifies genes specific for well-differentiated epithelial thyroid tumors. Cell Mol Biol (Noisy-le-grand) 51:177-186
38. Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, Kornacker K, LiVolsi V, Frankel W, Kloos RT, Eng C, Pellegata NS, de la Chapelle A 2001 Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA 98:15044-15049
39. Lubitz CC, Ugras SK, Kazam JJ, Zhu B, Scognamiglio T, Chen YT, Fahey III TJ 2006 Microarray analysis of thyroid nodule fine-needle aspirates accurately classifies benign and malignant lesions. J Mol Diagn 8:490-498
40. Finley DJ, Arora N, Zhu B, Gallagher L, Fahey III TJ 2004 Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab 89:3214-3223
41. Baris O, Savagner F, Nasser V, Loriod B, Granjeaud S, Guyetant S, Franc B, Rodien P, Rohmer V, Bertucci F, Birnbaum D, Malthiery Y, Reynier P, Houlgatte R 2004 Transcriptional profiling reveals coordinated up-regulation of oxidative metabolism genes in thyroid oncocytic tumors. J Clin Endocrinol Metab 89:994-1005
42. Mazzanti C, Zeiger MA, Costouros NG, Umbricht C, Westra WH, Smith D, Somervell H, Bevilacqua G, Alexander HR, Libutti SK, Costourous N 2004 Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res 64:2898-2903
43. Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, Mondellini P, Bongarzone I, Collini P, Gariboldi M, Pilotti S, Pierotti MA, Greco A 2004 Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 23:7436-7440
44. Jarzab B, Wiench M, Fujarewicz K, Simek K, Jarzab M, Oczko-Wojciechowska M, Wloch J, Czarniecka A, Chmielik E, Lange D, Pawlaczek A, Szpak S, Gubala E, Swierniak A 2005 Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res 65:1587-1597
45. Yano Y, Uematsu N, Yashiro T, Hara H, Ueno E, Miwa M, Tsujimoto G, Aiyoshi Y, Uchida K 2004 Gene expression profiling identifies platelet-derived growth factor as a diagnostic molecular marker for papillary thyroid carcinoma. Clin Cancer Res 10:2035-2043
46. Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, Zhu Z, Ciampi R, Roh M, Shedden K, Gauger P, Doherty G, Thompson NW, Hanash S, Koenig RJ, Nikiforov YE 2005 Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24:6646-6656
47. Wreesmann VB, Sieczka EM, Socci ND, Hezel M, Belbin TJ, Childs G, Patel SG, Patel KN, Tallini G, Prystowsky M, Shaha AR, Kraus D, Shah JP, Rao PH, Ghossein R, Singh B 2004 Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Res 64:3780-3789
48. Eszlinger M, Wiench M, Jarzab B, Krohn K, Beck M, Lauter J, Gubala E, Fujarewicz K, Swierniak A, Paschke R 2006 Meta- and reanalysis of gene expression profiles of hot and cold thyroid nodules and papillary thyroid carcinoma for gene groups. J Clin Endocrinol Metab 91:1934-1942
49. Stolf BS, Abreu CM, Mahler-Araujo MB, Dellamano M, Martins WK, de Carvalho MB, Curado MP, Diaz JP, Fabri A, Brentani H, Carvalho AF, Soares FA, Kowalski LP, Hirata Jr R, Reis LF 2005 Expression profile of malignant and non-malignant diseases of the thyroid gland reveals altered expression of a common set of genes in goiter and papillary carcinomas. Cancer Lett 227:59-73
50. Baris O, Mirebeau-Prunier D, Savagner F, Rodien P, Ballester B, Loriod B, Granjeaud S, Guyetant S, Franc B, Houlgatte R, Reynier P, Malthiery Y 2005 Gene profiling reveals specific oncogenic mechanisms and signaling pathways in oncocytic and papillary thyroid carcinoma. Oncogene 24:4155-4161
51. Eszlinger M, Krohn K, Beck M, Kipling D, Forbes-Robertson S, Lauter J, Tonjes A, Wynford-Thomas D, Paschke R 2006 Comparison of differential gene expression of hot and cold thyroid nodules with primary epithelial cell culture models by investigation of co-regulated gene sets. Biochim Biophys Acta 1763:263-271
52. Eszlinger M, Krohn K, Frenzel R, Kropf S, Tonjes A, Paschke R 2004 Gene expression analysis reveals evidence for inactivation of the TGF-β signaling cascade in autonomously functioning thyroid nodules. Oncogene 23:795-804
53. Wattel S, Mircescu H, Venet D, Burniat A, Franc B, Frank S, Andry G, Van Sande J, Rocmans P, Dumont JE, Detours V, Maenhaut C 2005 Gene expression in thyroid autonomous adenomas provides insight into their physiopathology. Oncogene 24:6902-6916
54. Eszlinger M, Krohn K, Berger K, Lauter J, Kropf S, Beck M, Fuhrer D, Paschke R 2005 Gene expression analysis reveals evidence for increased expression of cell cycle-associated genes and Gq-protein-protein kinase C signaling in cold thyroid nodules. J Clin Endocrinol Metab 90:1163-1170
55. Mazzaferri EL, Samaan N 1993 Endocrine tumors. Cambridge, UK: Blackwell; 278
56. Borrello MG, Alberti L, Fischer A, Degl'innocenti D, Ferrario C, Gariboldi M, Marchesi F, Allavena P, Greco A, Collini P, Pilotti S, Cassinelli G, Bressan P, Fugazzola L, Mantovani A, Pierotti MA 2005 Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci USA 102:14825-14830
57. Detours V, Wattel S, Venet D, Hutsebaut N, Bogdanova T, Tronko MD, Dumont JE, Franc B, Thomas G, Maenhaut C 2005 Absence of a specific radiation signature in post-Chernobyl thyroid cancers. Br J Cancer 92:1545-1552
58. Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R, Kruhoffer M, Orntoft T, Fusco A, Santoro M 2005 The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 115:1068-1081
59. Hoang-Vu C, Dralle H, Scheumann G, Maenhaut C, Horn R, von zur Muhlen A, Brabant G 1992 Gene expression of differentiation-and dedifferentiation markers in normal and malignant human thyroid tissues. Exp Clin Endocrinol 100:51-56
60. Loh KC, Greenspan FS, Dong F, Miller TR, Yeo PP 1999 Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 84:458-463
61. Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, Rabes HM, Fagin JA, Nikiforov YE 2005 Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 115:94-101
62. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA 2003 High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454-1457
63. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R, Sobrinho-Simoes M 2003 BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22:4578-4580
64. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399-5404
65. Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, Marino C, Avenia N, Rossi ED, Fadda G, Cavaliere A, Ribacchi R, Falorni A, Pontecorvi A, Pacini F, Pinchera A, Santeusanio F 2004 BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 89:2414-2420
66. Liu RT, Chen YJ, Chou FF, Li CL, Wu WL, Tsai PC, Huang CC, Cheng JT 2005 No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol (Oxf) 63:461-466
67. Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vicentini L, Beck-Peccoz P 2004 BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf) 61:239-243
68. Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, Kim SY, Kim SC, Hong SJ, Shong YK 2005 The BRAFV600E mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 63:588-593
69. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW, Nikiforov YE 2006 Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30:216-222
70. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S 2003 Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88:4393-4397
71. Cerutti JM, Delcelo R, Amadei MJ, Nakabashi C, Maciel RM, Peterson B, Shoemaker J, Riggins GJ 2004 A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. J Clin Invest 113:1234-1242
72. Fagin JA 2002 Minireview: branded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid. Mol Endocrinol 16:903-911
73. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM, Fletcher JA 2000 PAX8-PPARγ1 fusion oncogene in human thyroid carcinoma [corrected]. Science [Erratum (2000) 289:1474] 289:1357-1360
74. Marques AR, Espadinha C, Catarino AL, Moniz S, Pereira T, Sobrinho LG, Leite V 2002 Expression of PAX8-PPARγ 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 87:3947-3952
75. Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG, Nikiforov YE 2002 PAX8-PPARγ rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol 26:1016-1023
76. Cheung L, Messina M, Gill A, Clarkson A, Learoyd D, Delbridge L, Wentworth J, Philips J, Clifton-Bligh R, Robinson BG 2003 Detection of the PAX8-PPARγ fusion oncogene in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 88:354-357
77. Gregory PJ, Wang X, Allard BL, Sahin M, Wang XL, Hay ID, Hiddinga HJ, Deshpande SS, Kroll TG, Grebe SK, Eberhardt NL, McIver B 2004 The PAX8/PPARγ fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARγ inhibition. Oncogene 23:3634-3641
78. French CA, Alexander EK, Cibas ES, Nose V, Laguette J, Faquin W, Garber J, Moore Jr F, Fletcher JA, Larsen PR, Kroll TG 2003 Genetic and biological subgroups of low-stage follicular thyroid cancer. Am J Pathol 162:1053-1060
79. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, Tallini G, Kroll TG, Nikiforov YE 2003 RAS point mutations and PAX8-PPARγ rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 88:2318-2326
80. Eszlinger M, Krohn K, Kratzsch J, Voigt C, Paschke R 2001 Growth factor expression in cold and hot thyroid nodules. Thyroid 11:125-135
81. Gärtner R, Schopohl D, Schaefer S, Dugrillon A, Erdmann A, Toda S, Bechtner G 1997 Regulation of transforming growth factor β1 messenger ribonucleic acid expression in porcine thyroid follicles in vitro by growth factors, iodine, or δ-iodolactone. Thyroid 7:633-640
82. Voigt C, Holzapfel H, Paschke R 2000 Expression of β-arrestins in toxic and cold thyroid nodules. FEBS Lett 486:208-212
83. Chen W, Kirkbride KC, How T, Nelson CD, Mo J, Frederick JP, Wang XF, Lefkowitz RJ, Blobe GC 2003 Beta-arrestin 2 mediates endocytosis of type III TGF-β receptor and down-regulation of its signaling. Science 301:1394-1397
84. Frenzel R, Krohn K, Eszlinger M, Tonjes A, Paschke R 2005 Sialylation of human thyrotropin receptor improves and prolongs its cell-surface expression. Mol Pharmacol 68:1106-1113
85. Persani L, Lania A, Alberti L, Romoli R, Mantovani G, Filetti S, Spada A, Conti M 2000 Induction of specific phosphodiesterase isoforms by constitutive activation of the cAMP pathway in autonomous thyroid adenomas. J Clin Endocrinol Metab 85:2872-2878
86. Voigt C, Holzapfel HP, Meyer S, Paschke R 2004 Increased expression of G-protein-coupled receptor kinases 3 and 4 in hyper-functioning thyroid nodules. J Endocrinol 182:173-182
87. Eszlinger M, Holzapfel HP, Voigt C, Arkenau C, Paschke R 2004 RGS 2 expression is regulated by TSH and inhibits TSH receptor signaling. Eur J Endocrinol 151:383-390
88. Tonjes A, Miedlich S, Holzapfel HP, Eszlinger M, Arkenau C, Paschke R 2004 Expression of regulators of G protein signaling mRNA is differentially regulated in hot and cold thyroid nodules. Thyroid 14:896-901
89. Uyttersprot N, Costagliola S, Dumont JE, Miot F 1999 Requirement for cAMP-response element (CRE) binding protein/CRE modulator transcription factors in thyrotropin-induced proliferation of dog thyroid cells in primary culture. Eur J Biochem 259:370-378
90. Finley DJ, Lubitz CC, Wei C, Zhu B, Fahey III TJ 2005 Advancing the molecular diagnosis of thyroid nodules: defining benign lesions by molecular profiling. Thyroid 15:562-568
91. Krohn K, Fuhrer D, Bayer Y, Eszlinger M, Brauer V, Neumann S, Paschke R 2005 Molecular pathogenesis of euthyroid and toxic multinodular goiter. Endocr Rev 26:504-524
92. Krohn K, Emmrich P, Ott N, Paschke R 1999 Increased thyroid epithelial cell proliferation in toxic thyroid nodules. Thyroid 9:241-246
93. Krohn K, Stricker I, Emmrich P, Paschke R 2003 Cold thyroid nodules show a marked increase in proliferation markers. Thyroid 13:569-575
94. Esapa CT, Johnson SJ, Kendall-Taylor P, Lennard TW, Harris PE 1999 Prevalence of Ras mutations in thyroid neoplasia. Clin Endocrinol (Oxf) 50:529-535
95. Krohn K, Reske A, Ackermann F, Muller A, Paschke R 2001 Ras mutations are rare in solitary cold and toxic thyroid nodules. Clin Endocrinol (Oxf) 55:241-248
96. Gire V, Wynford-Thomas D 2000 RAS oncogene activation induces proliferation in normal human thyroid epithelial cells without loss of differentiation. Oncogene 19:737-744
97. Bachrach LK, Eggo MC, Mak WW, Burrow GN 1985 Phorbol esters stimulate growth and inhibit differentiation in cultured thyroid cells. Endocrinology 116:1603-1609
98. Haye B, Aublin JL, Champion S, Lambert B, Jacquemin C 1985 Tetradecanoyl phorbol-13-acetate counteracts the responsiveness of cultured thyroid cells to thyrotropin. Biochem Pharmacol 34:3795-3802
99. Roger PP, Reuse S, Servais P, Van Heuverswyn B, Dumont JE 1986 Stimulation of cell proliferation and inhibition of differentiation expression by tumor-promoting phorbol esters in dog thyroid cells in primary culture. Cancer Res 46:898-906
100. Takasu N, Shimizu Y, Yamada T 1987 Tumour promoter 12-O-tetradecanoylphorbol 13-acetate and epidermal growth factor stimulate proliferation and inhibit differentiation of porcine thyroid cells in primary culture. J Endocrinol 113:485-487
101. Vassart G, Dumont JE 1992 The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocr Rev 13:596-611
102. Van Herle AJ, Agatep ML, Padua III DN, Totanes TL, Canlapan DV, Van Herle HM, Juillard GJ 1990 Effects of 13 cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA R0 82 W-1) in vitro. J Clin Endocrinol Metab 71:755-763
103. Schmutzler C, Brtko J, Bienert K, Kohrle J 1996 Effects of retinoids and role of retinoic acid receptors in human thyroid carcinomas and cell lines derived therefrom. Exp Clin Endocrinol Diabetes 104(Suppl 4):16-19
104. Schreck R, Schnieders F, Schmutzler C, Kohrle J 1994 Retinoids stimulate type I iodothyronine 5′-deiodinase activity in human follicular thyroid carcinoma cell lines. J Clin Endocrinol Metab 79:791-798
105. Donovan M, Olofsson B, Gustafson AL, Dencker L, Eriksson U 1995 The cellular retinoic acid-binding proteins. J Steroid Biochem Mol Biol 53:459-465
106. Aogi K, Kitahara K, Buley I, Backdahl M, Tahara H, Sugino T, Tarin D, Goodison S 1998 Telomerase activity in lesions of the thyroid: application to diagnosis of clinical samples including fine-needle aspirates. Clin Cancer Res 4:1965-1970
107. Bernet VJ, Anderson J, Vaishnav Y, Solomon B, Adair CF, Saji M, Burman KD, Burch HB, Ringel MD 2002 Determination of galectin-3 messenger ribonucleic acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction. J Clin Endocrinol Metab 87:4792-4796
108. Casey MB, Lohse CM, Lloyd RV 2003 Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1. Endocr Pathol 14:55-60
109. Haugen BR, Nawaz S, Markham N, Hashizumi T, Shroyer AL, Werness B, Shroyer KR 1997 Telomerase activity in benign and malignant thyroid tumors. Thyroid 7:337-342
110. Inohara H, Honjo Y, Yoshii T, Akahani S, Yoshida J, Hattori K, Okamoto S, Sawada T, Raz A, Kubo T 1999 Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 85:2475-2484
111. Ippolito A, Vella V, La Rosa GL, Pellegriti G, Vigneri R, Belfiore A 2001 Immunostaining for Met/HGF receptor may be useful to identify malignancies in thyroid lesions classified suspicious at fine-needle aspiration biopsy. Thyroid 11:783-787
112. Mase T, Funahashi H, Koshikawa T, Imai T, Nara Y, Tanaka Y, Nakao A 2003 HBME-1 immunostaining in thyroid tumors especially in follicular neoplasm. Endocr J 50:173-177
113. Raphael SJ 2002 The meanings of markers: ancillary techniques in diagnosis of thyroid neoplasia. Endocr Pathol 13:301-311
114. Sack MJ, Astengo-Osuna C, Lin BT, Battifora H, LiVolsi VA 1997 HBME-1 immunostaining in thyroid fine-needle aspirations: a useful marker in the diagnosis of carcinoma. Mod Pathol 10:668-674
115. Saggiorato E, Cappia S, De Giuli P, Mussa A, Pancani G, Caraci P, Angeli A, Orlandi F 2001 Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. J Clin Endocrinol Metab 86:5152-5158
116. Kholova I, Ryska A, Ludvikova M, Cap J, Pecen L 2003 Dipeptidyl peptidase IV expression in thyroid cytology: retrospective histologically confirmed study. Cytopathology 14:27-31
117. Giannini R, Faviana P, Cavinato T, Elisei R, Pacini F, Berti P, Fontanini G, Ugolini C, Camacci T, De Ieso K, Miccoli P, Pinchera A, Basolo F 2003 Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens. Thyroid 13:765-770
118. Papotti M, Rodriguez J, De Pompa R, Bartolazzi A, Rosai J 2005 Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Mod Pathol 18:541-546
119. Prasad ML, Huang Y, Pellegata NS, de la Chapelle A, Kloos RT 2004 Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC. Histopathology 45:39-46
120. Saggiorato E, De Pompa R, Volante M, Cappia S, Arecco F, Dei Tos AP, Orlandi F, Papotti M 2005 Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer 12:305-317
121. Takano T, Miyauchi A, Matsuzuka F, Kuma K, Amino N 2000 Expression of oncofetal fibronectin messenger ribonucleic acid in fibroblasts in the thyroid: a possible cause of false positive results in molecular-based diagnosis of thyroid carcinomas. J Clin Endocrinol Metab 85:765-768
122. Grutzmann R, Boriss H, Ammerpohl O, Luttges J, Kalthoff H, Schackert HK, Kloppel G, Saeger HD, Pilarsky C 2005 Meta-analysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes. Oncogene 24:5079-5088
123. Kebebew E, Peng M, Reiff E, McMillan A 2006 Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms. Cancer 106:2592-2597
124. Venet D, Pecasse F, Maenhaut C, Bersini H 2001 Separation of samples into their constituents using gene expression data. Bioinformatics 17(Suppl 1):S279-S287
125. Lubitz CC, Fahey III TJ 2006 Gene expression profiling of thyroid tumors - clinical applicability. Nat Clin Pract Endocrinol Metab 2:472-473
126. Tan PK, Downey TJ, Spitznagel Jr EL, Xu P, Fu D, Dimitrov DS, Lempicki RA, Raaka BM, Cam MC 2003 Evaluation of gene expression measurements from commercial microarray platforms. Nucleic Acids Res 31:5676-5684
127. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO 2000 Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24:227-235
128. Kuo WP, Jenssen TK, Butte AJ, Ohno-Machado L, Kohane IS 2002 Analysis of matched mRNA measurements from two different microarray technologies. Bioinformatics 18:405-412
129. Larkin JE, Frank BC, Gavras H, Sultana R, Quackenbush J 2005 Independence and reproducibility across microarray platforms. Nat Methods 2:337-344
130. Bammler T, Beyer RP, Bhattacharya S, Boorman GA, Boyles A, Bradford BU, Bumgarner RE, Bushel PR, Chaturvedi K, Choi D, Cunningham ML, Deng S, Dressman HK, Fannin RD, Farin FM, Freedman JH, Fry RC, Harper A, Humble MC, Hurban P, Kavanagh TJ, Kaufmann WK, Kerr KF, Jing L, Lapidus JA, Lasarev MR, Li J, Li YJ, Lobenhofer EK, Lu X, Malek RL, Milton S, Nagalla SR, O'Malley JP, Palmer VS, Pattee P, Paules RS, Perou CM, Phillips K, Qin LX, Qiu Y, Quigley SD, Rodland M, Rusyn I, Samson LD, Schwartz DA, Shi Y, Shin JL, Sieber SO, Slifer S, Speer MC, Spencer PS, Sproles DI, Swenberg JA, Suk WA, Sullivan RC, Tian R, Tennant RW, Todd SA, Tucker CJ, Van Houten B, Weis BK, Xuan S, Zarbl H 2005 Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods 2:351-356
131. Irizarry RA, Warren D, Spencer F, Kim IF, Biswal S, Frank BC, Gabrielson E, Garcia JG, Geoghegan J, Germino G, Griffin C, Hilmer SC, Hoffman E, Jedlicka AE, Kawasaki E, Martinez-Murillo F, Morsberger L, Lee H, Petersen D, Quackenbush J, Scott A, Wilson M, Yang Y, Ye SQ, Yu W 2005 Multiple-laboratory comparison of microarray platforms. Nat Methods 2:345-350
132. Griffith OL, Melck A, Jones SJ, Wiseman SM 2006 Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. J Clin Oncol 24:5043-5051
133. Bruno R, Ferretti E, Tosi E, Arturi F, Giannasio P, Mattei T, Scipioni A, Presta I, Morisi R, Gulino A, Filetti S, Russo D 2005 Modulation of thyroid-specific gene expression in normal and nodular human thyroid tissues from adults: an in vivo effect of thyrotropin. J Clin Endocrinol Metab 90:5692-5697
134. Eszlinger M, Krohn K, Toenjes A, Läuter J, Paschke R 2007 Variability of gene expression of "normal" thyroid tissue. Exp Clin Endocrinol Diabetes 115(Suppl 1):8 (Abstract)
135. Gharib H 1997 Changing concepts in the diagnosis and management of thyroid nodules. Endocrinol Metab Clin North Am 26:777-800
136. Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A, Inohara H, Marandino F, Orlandi F, Nardi F, Vecchione A, Tecce R, Larsson O 2001 Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 357:1644-1650
137. de Micco C, Ruf J, Chrestian MA, Gros N, Henry JF, Carayon P 1991 Immunohistochemical study of thyroid peroxidase in normal, hyperplastic, and neoplastic human thyroid tissues. Cancer 67:3036-3041
138. Fagin JA 2002 Perspective: lessons learned from molecular genetic studies of thyroid cancer-insights into pathogenesis and tumor-specific therapeutic targets. Endocrinology 143:2025-2028
139. Gimm O 2001 Thyroid cancer. Cancer Lett 163:143-156
140. Cohen Y, Rosenbaum E, Clark DP, Zeiger MA, Umbricht CB, Tufano RP, Sidransky D, Westra WH 2004 Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res 10:2761-2765
141. Jin L, Sebo TJ, Nakamura N, Qian X, Oliveira A, Majerus JA, Johnson MR, Lloyd RV 2006 BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol 15:136-143
142. Rowe LM, Bentz BM, Bentz JM 2006 Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules. Cytojournal 3:10
143. Salvatore G, Giannini R, Faviana P, Caleo A, Migliaccio I, Fagin JA, Nikiforov YE, Troncone G, Palombini L, Basolo F, Santoro M 2004 Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 89:5175-5180
144. Malamos B, Koutras DA, Kostamis P, Rigopoulos GA, Zerefos NS, Yataganas XA 1967 Endemic goitre in Greece: a study of 379 twin pairs. J Med Genet 4:16-18
145. Hadjidakis SG, Koutras DA, Daikos GK 1964 Endemic goitre in Greece: family studies. J Med Genet 38:82-87
146. Bignell GR, Canzian F, Shayeghi M, Stark M, Shugart YY, Biggs P, Mangion J, Hamoudi R, Rosenblatt J, Buu P, Sun S, Stoffer SS, Goldgar DE, Romeo G, Houlston RS, Narod SA, Stratton MR, Foulkes WD 1997 Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer. Am J Hum Genet 61:1123-1130
147. Capon F, Tacconelli A, Giardina E, Sciacchitano S, Bruno R, Tassi V, Trischitta V, Filetti S, Dallapiccola B, Novelli G 2000 Mapping a dominant form of multinodular goiter to chromosome Xp22. Am J Hum Genet 67:1004-1007
148. Neumann S, Willgerodt H, Ackermann F, Reske A, Jung M, Reis A, Paschke R 1999 Linkage of familial euthyroid goiter to the multinodular goiter-1 locus and exclusion of the candidate genes thyroglobulin, thyroperoxidase, and Na+/I- symporter. J Clin Endocrinol Metab 84:3750-3756
149. Bayer Y, Neumann S, Meyer B, Ruschendorf F, Reske A, Brix T, Hegedus L, Langer P, Nurnberg P, Paschke R 2004 Genome-wide linkage analysis reveals evidence for four new susceptibility loci for familial euthyroid goiter. J Clin Endocrinol Metab 89:4044-4052
150. Bottcher Y, Eszlinger M, Tonjes A, Paschke R 2005 The genetics of euthyroid familial goiter. Trends Endocrinol Metab 16:314-319
151. Rodrigues RF, Roque L, Rosa-Santos J, Cid O, Soares J 2004 Chromosomal imbalances associated with anaplastic transformation of follicular thyroid carcinomas. Br J Cancer 90:492-496
152. Roque L, Rodrigues R, Pinto A, Moura-Nunes V, Soares J 2003 Chromosome imbalances in thyroid follicular neoplasms: a comparison between follicular adenomas and carcinomas. Genes Chromosomes Cancer 36:292-302
153. Castro P, Eknaes M, Teixeira MR, Danielsen HE, Soares P, Lothe RA, Sobrinho-Simoes M 2005 Adenomas and follicular carcinomas of the thyroid display two major patterns of chromosomal changes. J Pathol 206:305-311
154. Wreesmann VB, Ghossein RA, Hezel M, Banerjee D, Shaha AR, Tuttle RM, Shah JP, Rao PH, Singh B 2004 Follicular variant of papillary thyroid carcinoma: genome-wide appraisal of a controversial entity. Genes Chromosomes Cancer 40:355-364
155. Wasenius VM, Hemmer S, Kettunen E, Knuutila S, Franssila K, Joensuu H 2003 Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin Cancer Res 9:68-75
156. Prasad ML, Pellegata NS, Kloos RT, Barbacioru C, Huang Y, de la Chapelle A 2004 CITED1 protein expression suggests papillary thyroid carcinoma in high throughput tissue microarray-based study. Thyroid 14:169-175
157. Zou M, Famulski KS, Parhar RS, Baitei E, Al Mohanna FA, Farid NR, Shi Y 2004 Microarray analysis of metastasis-associated gene expression profiling in a murine model of thyroid carcinoma pulmonary metastasis: identification of S100A4 (Mts1) gene overexpression as a poor prognostic marker for thyroid carcinoma. J Clin Endocrinol Metab 89:6146-6154
158. Chen KT, Lin JD, Chao TC, Hsueh C, Chang CA, Weng HF, Chan EC 2001 Identifying differentially expressed genes associated with metastasis of follicular thyroid cancer by cDNA expression array. Thyroid 11:41-46
159. Hamada A, Mankovskaya S, Saenko V, Rogounovitch T, Mine M, Namba H, Nakashima M, Demidchik Y, Demidchik E, Yamashita S 2005 Diagnostic usefulness of PCR profiling of the differentially expressed marker genes in thyroid papillary carcinomas. Cancer Lett 224:289-301
160. Takano T, Hasegawa Y, Miyauchi A, Matsuzuka F, Yoshida H, Kuma K, Hayashi N, Nakamori S, Amino N 2002 Quantitative analysis of osteonectin mRNA in thyroid carcinomas. Endocr J 49:511-516
161. Takano T, Miyauchi A, Yoshida H, Kuma K, Amino N 2004 High-throughput differential screening of mRNAs by serial analysis of gene expression: decreased expression of trefoil factor 3 mRNA in thyroid follicular carcinomas. Br J Cancer 90:1600-1605
162. Jacques C, Baris O, Prunier-Mirebeau D, Savagner F, Rodien P, Rohmer V, Franc B, Guyetant S, Malthiery Y, Reynier P 2005 Two-step differential expression analysis reveals a new set of genes involved in thyroid oncocytic tumors. J Clin Endocrinol Metab 90:2314-2320
163. Haugen BR, Larson LL, Pugazhenthi U, Hays WR, Klopper JP, Kramer CA, Sharma V 2004 Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. J Clin Endocrinol Metab 89:272-280
164. Aksoy M, Giles Y, Kapran Y, Terzioglu T, Tezelman S 2005 Expression of bcl-2 in papillary thyroid cancers and its prognostic value. Acta Chir Belg 105:644-648